Double Dipping at NIH: "the Gaming Must End" – Editorial WashPost

Double Dipping at NIH: “the Gaming Must End” – Editorial WashPost

Tue, 6 Jul 2004

Monday’s Washington Post editorial took a critical of the corrupting influence of the pharmaceutical industry on scientists at the National Institutes of Health. The agency’s “lax ethics rules, laxly enforced” has resulted in scientists “[pocketing] fat consulting fees, at times for work that overlapped, or even conflicted, with their government jobs.”

These revelations were first uncovered by David Willman of The Los Angeles Times who reported on December 7, 2003 that the former director of the NIH, Dr. Harold Varmus, had lifted the enforcement of government ethics rules for NIH staff, leading “more than 94% of the agency’s top-paid employees to keep their consulting income confidential.”

Following questioning by the House subcommittee on oversight and investigations (May 13, 2004), NIH director Dr. Elias Zerhouni, convened a panel that conducted nothing but a whitewash investigation. Committee chair, James Greenwood, called the NIH ethics policy, “the option of corruption,” and convened an investigation of his own. When NIH officials failed to hand over documents requested by the committee, Greenwood went directly to the pharmaceutical companies, uncovering additional evidence of corruption.

One example involved a high ranking official at the National Institute of Mental Health-which the LA Times did not investigate. The Washington Post reported that: “drug giant Pfizer Inc. reported that Trey Sunderland, a researcher at the [NIMH], was paid $517,000 in fees, honoraria and expense reimbursements related to consulting arrangements with the company over the past five years. Greenwood said the information was not on Sunderland’s financial disclosure reports as required by federal ethics rules.”

Only after he was confronted with additional evidence-and criticism around the country–did Dr. Zerhouni revise his original, unacceptable recommendations for reform, and seriously address the malaise by laying down restrictions on outside consultancies, requiring full disclosure of any that are engaged in.

The Washington Post editorial wistfully suggests that the new restrictions “may turn out not to be strong enough medicine.” The Post acknowledges that: “It’s a legitimate question whether any outside consulting at all should be allowed.”

The Alliance for Human Research Protection (AHRP) notes the deafening silence in the pages of the New York Times throughout the public disclosure proceedings in which a body of evidence unfolded, laying bare evidence of secret cash payments to top NIH scientists. The Times did not see fit to report these matters to its readers. One is led to wonder, why evidence of institutional corruption at the nation’s prestigious medical research center, one that set the tone for the medical community-is not “fit to print,” but examples of corruption by individual practitioner-hustlers are “fit to print?” See: Medical Marketing : Treatment by Incentive; As Doctor Writes Prescription, Drug Company Writes a Check By GARDINER HARRIS, Section 1 , Page 1 , Column 1

Contact: Vera Hassner Sharav
Tel: 212-595-8974
Double Dipping at NIH
Monday, July 5, 2004; Page A16

THE NATIONAL Institutes of Health in recent years has suffered from a set of lax ethics rules, laxly enforced. Freed in 1995 from regulations that had limited their outside income, some senior NIH scientists pocketed fat consulting fees, at times for work that overlapped, or even conflicted, with their government jobs.

In one instance recently uncovered by congressional investigators, a researcher at the National Institute of Mental Health, one of the NIH’s 27 components, was paid $517,000 by the drug company Pfizer over five years; the money wasn’t cleared with agency officials or reported on his financial disclosure form. In another, a National Cancer Institute lab chief, along with a colleague from the Food and Drug Administration, was assigned to collaborate with a private company to develop cancer testing; the pair then signed a consulting deal with one of the firm’s competitors. The skin diseases branch chief at the National Institute of Arthritis was retained to testify as an expert witness on the acne drug Accutane, at a reported hourly rate of $600; among his points was the alleged inadequacy of government-approved warnings on the drug.

“I’ve reached the conclusion that drastic changes are needed,” NIH director Elias Zerhouni told a House committee. Dr. Zerhouni’s prescription, which goes beyond his original recommendations, may turn out not to be strong enough medicine. It’s a legitimate question whether any outside consulting at all should be allowed. But given the unusual role of the NIH — its scientists are more comparable to academic researchers than to government regulators like those at the FDA — the Zerhouni approach is worth a try.

Senior employees wouldn’t be allowed to do outside consulting. Those allowed to engage in consulting work would be limited to 400 hours annually; their pay couldn’t amount to more than a quarter of their government salary (and no more than half could come from any one source). None of the consulting work could involve their government duties. All consulting would have to be publicly disclosed. NIH employees couldn’t serve on corporate boards or accept stock or stock options as compensation; they couldn’t hold more than $5,000 worth of stock in any pharmaceutical or biotechnology firm. And no consulting deals would be allowed with universities that get NIH funding.

One of the arguments in favor of allowing continued outside consulting work is not to inhibit the NIH’s ability to recruit and retain top-tier scientists, who could command higher pay in the private sector. Another sneaky way around the pay disparity has been for the NIH to exploit a loophole designed to let the government hire “special consultants” above the usual federal pay rates. This exception has been used widely at the NIH, with 21 of 27 institute and center directors paid as special consultants, at salaries of up to $235,000. Nearly one-third of NIH employees hired last year were brought on using this inartful dodge.

As with the Securities and Exchange Commission, which has been granted exemptions from regular government pay scales because of difficulties in competing with the private sector to attract lawyers and accountants, we don’t begrudge giving the NIH some flexibility in setting salaries. But this can’t be taken too far: There are rewards to working at the NIH that alleviate the pay differential. And salaries ought to be set in an above-board manner. As Rep. James C. Greenwood (R-Pa.), who has overseen the congressional probe of the NIH as chair of the Energy and Commerce subcommittee on oversight and investigations, put it, “The gaming must end.”

C 2004 The Washington Post Company

FAIR USE NOTICE: This may contain copyrighted (C ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit. _______________________________